- Home
- RDHL vs RVYL Comparison
RDHL vs RVYL Comparison
Compare RDHL & RVYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- RVYL
- Stock Information
- Founded
- RDHL 2009
- RVYL 2007
- Country
- RDHL Israel
- RVYL United States
- Employees
- RDHL N/A
- RVYL N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- RVYL Professional Services
- Sector
- RDHL Health Care
- RVYL Consumer Discretionary
- Exchange
- RDHL Nasdaq
- RVYL Nasdaq
- Market Cap
- RDHL 8.6M
- RVYL 8.4M
- IPO Year
- RDHL N/A
- RVYL N/A
- Fundamental
- Price
- RDHL $6.99
- RVYL $1.40
- Analyst Decision
- RDHL
- RVYL Hold
- Analyst Count
- RDHL 0
- RVYL 1
- Target Price
- RDHL N/A
- RVYL N/A
- AVG Volume (30 Days)
- RDHL 21.2K
- RVYL 163.3K
- Earning Date
- RDHL 12-27-2024
- RVYL 11-14-2024
- Dividend Yield
- RDHL N/A
- RVYL N/A
- EPS Growth
- RDHL N/A
- RVYL N/A
- EPS
- RDHL N/A
- RVYL N/A
- Revenue
- RDHL $3,707,000.00
- RVYL $63,529,000.00
- Revenue This Year
- RDHL $224.90
- RVYL N/A
- Revenue Next Year
- RDHL $82.69
- RVYL $48.92
- P/E Ratio
- RDHL N/A
- RVYL N/A
- Revenue Growth
- RDHL N/A
- RVYL 16.09
- 52 Week Low
- RDHL $6.35
- RVYL $0.89
- 52 Week High
- RDHL $43.50
- RVYL $5.48
- Technical
- Relative Strength Index (RSI)
- RDHL 42.91
- RVYL 45.89
- Support Level
- RDHL $7.09
- RVYL $1.37
- Resistance Level
- RDHL $7.44
- RVYL $1.65
- Average True Range (ATR)
- RDHL 0.53
- RVYL 0.20
- MACD
- RDHL -0.03
- RVYL -0.00
- Stochastic Oscillator
- RDHL 12.36
- RVYL 18.97
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.